Compare Huntington Bancshares Incorporated (HBAN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs BIO-TECHNE Corp — how do they compare? Huntington Bancshares Incorporated trades at $15.39 (market cap $30.66B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Huntington Bancshares Incorporated is far larger — about 2.7× BIO-TECHNE Corp's market cap, and Huntington Bancshares Incorporated pays the higher dividend (4.09%). Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and BIO-TECHNE Corp for 63 Days on average.
| HBAN | TECH | |
|---|---|---|
Market Cap | $30.66B | $11.37B |
Volume | 30,269,931 | 3,153,511 |
Sector | Financials | Health |
52-Week High | $19.27 | $72.61 |
52-Week Low | $15.02 | $43.31 |
Typical Hold Time | 52 Days | 63 Days |
Enterprise Value | $49.17B | $11.40B |
Dividend Yield | 4.09% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.17, down 1.04% on the day, reflecting recent pressure from margin headwinds and a lowered 2027 earnings outlook. The stock shows a bearish technical signal with moving averages indicating selling pressure, while fundamentals reveal a P/E of 11.67 and net income margin of 24.77%. Recent news highlights increased options activity and a new $0.16 dividend declaration, but investor sentiment is cautious amid interest rate challenges.
HBAN presents a mixed outlook with a consensus price target of $19.60 suggesting 29% upside, supported by shareholder returns via buybacks and dividends. However, risks include persistent net interest margin compression, competitive lending pressures, and macroeconomic sensitivity. The stock's valuation appears reasonable, but earnings misses and guidance cuts warrant close monitoring of upcoming Q3 2026 results for directional clarity.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
